These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39180720)

  • 1. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
    Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1100-1106. PubMed ID: 39180720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
    Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
    Takashima A; Ishiguro M; Sasaki K; Machida R; Nagashima F; Imaizumi J; Hamaguchi T; Yamamoto Y; Masuishi T; Asayama M; Ueno H; Shinozaki K; Kudo T; Machida N; Matsuoka H; Ishida H; Yamaguchi T; Nogami H; Yamada T; Takegawa N; Kito Y; Tonoike Y; Sawada R; Tsukamoto S; Kanemitsu Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1107-1114. PubMed ID: 39210583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
    Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
    BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Yokoyama K; Wasano K; Sasaki K; Machida R; Nakahira M; Kitamura K; Sakagami T; Takeshita N; Ohkoshi A; Suzuki M; Tateya I; Morishita Y; Sekimizu M; Nakayama M; Koyama T; Shibata H; Miyamaru S; Kiyota N; Hanai N; Homma A
    Jpn J Clin Oncol; 2024 Oct; 54(10):1115-1122. PubMed ID: 39206595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
    Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost-a survey in Japan.
    Osawa T; Sasaki K; Machida R; Matsumoto T; Matsui Y; Kitamura H; Nishiyama H
    Jpn J Clin Oncol; 2024 Oct; 54(10):1062-1070. PubMed ID: 38843876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cost of chemotherapy for gynecologic malignancies.
    Takahashi N; Seki T; Sasaki K; Machida R; Ishikawa M; Yunokawa M; Matsuoka A; Kagabu M; Yamaguchi S; Hiranuma K; Ohnishi J; Sato T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1078-1083. PubMed ID: 39023439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).
    Watanabe K; Sasaki K; Machida R; Shimizu J; Yamane Y; Tamiya M; Saito S; Takada Y; Yoh K; Yoshioka H; Murakami H; Kitazono S; Goto Y; Horinouchi H; Ohe Y
    Jpn J Clin Oncol; 2024 Oct; 54(10):1084-1092. PubMed ID: 39158350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
    Kashiwa M; Matsushita R
    Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
    Imaoka H; Sasaki K; Machida R; Nagano H; Satoi S; Ikeda M; Kobayashi S; Yamashita T; Okusaka T; Ido A; Hatano E; Miwa H; Ueno M; Nakao K; Shimizu S; Kuramochi H; Sakamori R; Tsumura H; Okano N; Shioji K; Shirakawa H; Akutsu N; Tsuji K; Ishii H; Umemoto K; Asagi A; Ueno M;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1071-1077. PubMed ID: 38843879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study.
    Komatsu Y; Hironaka S; Tanizawa Y; Cai Z; Piao Y; Boku N
    Adv Ther; 2022 Jan; 39(1):296-313. PubMed ID: 34716560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
    Chen XZ; Jiang K; Hu JK; Zhang B; Gou HF; Yang K; Chen ZX; Chen JP
    World J Gastroenterol; 2008 May; 14(17):2715-22. PubMed ID: 18461656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
    Ter Veer E; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
    Int J Cancer; 2018 Jul; 143(2):438-448. PubMed ID: 29451302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients.
    Iwatani T; Sasaki K; Machida R; Shien T; Hara F; Fujisawa T; Takano Y; Kobayashi Y; Saimura M; Koizumi K; Terada M; Sasada S; Saito K; Sumiyoshi M; Iwata H
    Jpn J Clin Oncol; 2024 Oct; 54(10):1093-1099. PubMed ID: 39178176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group.
    Motomura K; Sasaki K; Sugii N; Yamaguchi S; Inoue H; Oshima A; Tanaka K; Otani Y; Shirahata M; Shibahara I; Nagane M; Tsuzuki S; Matsutani T; Tsukamoto Y; Kijima N; Asano K; Ohno M; Inoue A; Mineharu Y; Miyake K; Mitobe Y; Hanihara M; Kawanishi Y; Deguchi S; Saito M; Matsuda R; Ujifuku K; Arita H; Sato Y; Yamashita S; Yonezawa U; Yamaguchi J; Momii Y; Ogawa T; Kambe A; Ohba S; Fukai J; Saito N; Kinoshita M; Sumi K; Otani R; Uzuka T; Takebe N; Koizumi S; Saito R; Arakawa Y; Narita Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1123-1131. PubMed ID: 39223700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
    Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
    Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.